Skip to main content
About
Company Overview
Corporate Policies
Governance Policies
Team
Partners
Careers
Research
Clinical Trials
Publications
Pipeline
Investors
Newsroom
Contact
Facebook
Twitter
Linkedin
MENU
Home
About
Company Overview
Team
Partners
Careers
Patient Resource
Pipeline
Investors
Newsroom
Contact
Home
Investors
Overview
Events and Presentations
Stock Info
Financials
Governance
Board of Directors
Executive Management
Committee Composition
Resources
Shareholder Info
FAQs
Email Alerts
Newsroom
Press Releases
Videos
Press Releases
Home
Investors
Overview
Events and Presentations
Stock Info
Financials
Governance
Board of Directors
Executive Management
Committee Composition
Resources
Shareholder Info
FAQs
Email Alerts
Newsroom
Press Releases
Videos
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2021
2020
2019
2018
2017
2016
12/01/2021
Tetra Bio-Pharma Announces Up To $13.0 Million Marketed Public Offering of Units
11/29/2021
QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols
11/29/2021
Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™
11/04/2021
Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering
10/21/2021
Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency
10/14/2021
Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™
10/05/2021
REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.
09/02/2021
Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™
07/29/2021
Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue
07/22/2021
Tetra Bio-Pharma Engages Christine Caron as Patient Partner
07/12/2021
Tetra Bio-Pharma Accelerates REBORN1© Trial
06/25/2021
Tetra Bio-Pharma Announces Change in Management
06/21/2021
Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003
06/02/2021
Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
05/28/2021
Tetra Bio-Pharma Announces Voting Results of 2021 Annual General and Special Meeting
05/28/2021
Tetra Bio-Pharma Announces Clinical Advancements and Establishment of At-the-Market Equity Program
05/21/2021
Tetra Bio-Pharma Announces Exercise of Over-Allotment Option in Connection with Bought Deal Financing
05/18/2021
Tetra Bio-Pharma Inc. Announces Changes to its Board of Directors and the Filing of a Supplement to its Management Information Circular
05/17/2021
Tetra Bio-Pharma Announces Closing of Bought Deal Offering
05/11/2021
Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain
05/10/2021
Tetra Bio-Pharma Announces $10 Million "Bought Deal" Public Offering
05/06/2021
Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial
05/05/2021
Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
05/04/2021
Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals
05/03/2021
Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
04/28/2021
Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority
04/23/2021
Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial
04/15/2021
Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis
04/14/2021
Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada
04/05/2021
FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients
04/01/2021
Tetra Bio-Pharma Receives Second Compliant Rating on Inspection from Health Canada
03/30/2021
Health Canada Provides Positive Feedback on Tetra Bio-Pharma’s Application for ARDS-003 to be Studied in COVID-19 Patients at Risk of Developing Acute Respiratory Distress Syndrome
03/26/2021
Tetra Bio-Pharma Initiates Additional Studies on Leading Drug Candidate ARDS-003
03/18/2021
Tetra Bio-Pharma Receives Compliant Rating on Inspection from Health Canada
03/15/2021
Tetra Bio-Pharma Provides Status of Its New Drug Submission Application in Canada
03/08/2021
Correction To Tetra Bio-Pharma News Release Dated February 25th
03/03/2021
Tetra Bio-Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
03/02/2021
Tetra Bio-Pharma Announces Closing of Bought Deal Offering
02/25/2021
Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios
02/23/2021
Tetra Bio-pharma Inc. Announces Upsizing of Previously Announced Offering
02/22/2021
Tetra Bio-Pharma Inc. Announces $10 Million Bought Deal Offering of Units
02/03/2021
Tetra Bio-Pharma Inc. Announces Closing of Non-Brokered Private Placement
02/03/2021
Tetra Bio-Pharma Creates the ENJOUCA Business Unit
01/29/2021
Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1(TM) Clinical Trial to Commence
01/27/2021
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement